This acquired resistance to anti-VEGF treatment is involved in other angiogenic pathways, compensating for the inhibiting effects on cancer cells (Li et al., 2014; Choi et al., 2015; Mahdi et al., 2019; Yin et al., 2019). This evidence concerns the gene VEGFA and cancer.